Search tips
Search criteria 


Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
J Psychiatry Neurosci. 1992 November; 17(5): 195–197.
PMCID: PMC1188455

The addition of intravenous caffeine during an amobarbital interview.


Although the amobarbital interview is an effective means of temporarily relieving catatonic mutism, some catatonic patients simply fall asleep during an amobarbital interview. We are examining the feasibility of administering intravenous caffeine benzoate during an amobarbital interview to prevent patients from falling asleep. This paper describes an open trial of the administration of 500 mg caffeine benzoate during amobarbital interviews with ten patients. The procedure was well tolerated, but further studies are needed to determine whether or not caffeine is an advantage over amobarbital alone.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (384K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Abrams R, Taylor MA. Catatonia. A prospective clinical study. Arch Gen Psychiatry. 1976 May;33(5):579–581. [PubMed]
  • Acevedo AG, Smith JK. Adverse reaction to use of caffeine in ECT. Am J Psychiatry. 1988 Apr;145(4):529–530. [PubMed]
  • Hurwitz TA. Narcosuggestion in chronic conversion symptoms using combined intravenous amobarbital and methylphenidate. Can J Psychiatry. 1988 Mar;33(2):147–152. [PubMed]
  • Jaffe Richard, Brubaker Gillian, Dubin William R, Roemer Richard. Caffeine-Associated Cardiac Dysrhythmia During ECT: Report of Three Cases. Convuls Ther. 1990;6(4):308–313. [PubMed]
  • Kellner CH, Bachman DL. Olfactory hallucination after intravenous caffeine. Am J Psychiatry. 1992 Mar;149(3):422–422. [PubMed]
  • Lewis JL, Santos AB, Knox EP. Inducing catatonic patients to eat with daily administration of amobarbital sodium. South Med J. 1989 Oct;82(10):1315–1316. [PubMed]
  • McCall W Vaughn. The Response to an Amobarbital Interview as a Predictor of Therapeutic Outcome in Patients with Catatonic Mutism. Convuls Ther. 1992;8(3):174–178. [PubMed]
  • McCall WV, Shelp FE, McDonald WM. Controlled investigation of the amobarbital interview for catatonic mutism. Am J Psychiatry. 1992 Feb;149(2):202–206. [PubMed]
  • Neki JS, Kishore B. Narcostimulation in depressive states. Am J Psychiatry. 1968 Mar;124(9):1196–1201. [PubMed]
  • Shale JH, Gelenberg AJ. The amobarbital interview. Mil Med. 1980 Dec;145(12):825–828. [PubMed]
  • Shapira Baruch, Zohar Joseph, Newman Michael, Drexler Heinz, Belmaker RH. Potentiation of Seizure Length and Clinical Response to Electroconvulsive Therapy by Caffeine Pretreatment: A Case Report. Convuls Ther. 1985;1(1):58–60. [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association